Jui J, 327
Junquera ML, 761
Justus S, 311

K

Kabamba-Mukadi B, 297
Kahn RH, 360
Kalichman SC, 727
Kamb ML, 52, 469
Kambugu F, 650
Kamidono S, 180
Kao Y-M, 740
Kaplan AH, 455
Katsivo MN, 460
Kaufman JS, 149, 533
Kawabata M, 180
Kaydos-Daniels SC, 659
Kazatchkine MD, 96
Kenney K, 552
Kent CK, 469, 517, 596
Kerndt P, 552
Kessell E, 409
Kim JH, 568
Kinoshita S, 180
Klausner JD, 337, 517, 557, 596
Knapp JS, 73, 702
Kofuku T, 180
Kohn MA, 327
Kohn RP, 596
Köksalan K, 628
Kömeç S, 628
Korte JE, 166, 401
Koshiol JE, 748
Koutsky LA, 63
Kozlova A, 670
Krantz E, 508
Kreimer AR, 247
Krone MR, 337
Kuchinka-Koch A, 616
Kuhn L, 174
Kurth AE, 719
Kusimba J, 265
Kwok C, 561

L

Lackey PC, 225
Laffineur K, 297
Lago EG, 33
Laino L, 619
Lambert J, 488
La Montagne DS, 283
Lampinen TM, 492
Larro M, 637
Lau JTF, 568
Lau M, 568
Lavori P, 740
Ledsky R, 637
Lee FK, 753
Lee MV, 702
Leichliter JS, 665
Leone PA, 311, 455, 659
Lescano C, 205
Levin D, 740
Levine D, 205
Levine W, 20, 73, 702
Li L, 311
Li S-F, 221
Liao S-S, 643
Lidbrink P, 499
Liddon N, 421
Lindsey C, 469
Little M, 409
Liu S, 623
Long HT, 15
Louie B, 475
Loveless MO, 327
Lyketsos CG, 8
Lyons F, 317

M

Mackellar D, 475
Maeda S-I, 192
Maguire RA, 465
Mak DB, 449
Malinski C, 113
Malotte CK, 52, 469, 637
Manavi K, 322
Mandel JS, 643
Mark KE, 215
Markowitz LE, 20, 73, 581, 753
Maroufi A, 373
Marra CM, 196
Marrazzo JM, 283
Martich FA, 421
Martin DH, 273, 424
Martin DP, 719
Martinez-Salio A, 350
Marum LH, 522
Mâsse B, 100
Mathiti V, 727
May S, 67
Mayer KH, 201
Mays RM, 428
McClung MW, 154, 526
McCullough K, 143
McFarland W, 475
McKee KT, 443
McLean CA, 73
McMillan A, 322
McNutt LA, 631
McQuillan GM, 753
Mehta S, 123
Mendoza W, 337
Mercer CH, 380
Meyers A, 581
Meyers T, 117
Meyn L, 290
Meza R, 337
Michaud JM, 239, 611
Middlestadt S, 637
Millan-Juncos IM, 350
Miller E, 243
Miller GA, 337
Miller WC, 38, 455, 533, 659
Minnis A, 133
Miranda AE, 542
Miyai T, 517
Miyazawa T, 192
Moncada J, 273
Moreira RI, 67
Morris-Cunnington M, 243
Morrison CS, 561
Morrow RA, 508
Mosack KE, 682
Mosure DJ, 259
Mulcahy F, 317
Murphy S, 163
Myer L, 174
Myint M, 196

N

Nahmias AJ, 753
Ndinya-Achola JO, 265
Neilands TB, 475
Ness RB, 67, 301
Newbern EC, 533
Newman DR, 52
Nguyen S, 475
Nizharadze G, 670
Nsuami M, 424
Nyamukapa CA, 380

O

O'Connor NP, 702
O'Farrell N, 713
Ogilvie M, 322
Oh H-B, 305
Oh MK, 433
O'Hara HB, 265
Ohye RG, 702
Okada H, 180
Olthoff G, 637
Orr D, 393
Osazuwa EO, 460
Otero L, 761
Otido JM, 265
Owen C, 691

P

Packel L, 409
Padian N, 133
Page-Shafer K, 542
Pair L, 236
Pala S, 619
Palefsky JM, 96
Palv G, 608
Pan S, 695
Papenfuss MR, 601
Parham P, 734
Park H, 305
Patnaik JL, 154, 526
Patrick LE, 283
Patton DL, 290
Paz-Bailey G, 20, 581
Pealer LN, 52
Perdue ST, 166, 401
Peres RL, 542
Perez-Martinez DA, 350
Peterman TA, 52, 469
Phillips DM, 346, 465
Pierangeli A, 619
Piketty C, 96
Pimenta J, 243, 748
Pinkerton SD, 547
Piper JM, 166, 401
Plant AJ, 449
Polyakova G, 670
Pool R, 650
Porta-Etessam J, 350
Potterat JJ, 65, 365, 709
Pourbohloul B, 388
Prince M, 682
Pugatch D, 205

Q

Qin FZG, 623
Quinn TC, 85, 273

R

Rabe LK, 290
Rajan L, 393
Rank R, 257
Ratner D, 143
Rawstron SA, 123
Reid G, 460
Rein DB, 325
Remon J-P, 229
Richter HE, 236
Ritchie JM, 57
Robinson NJ, 243
Rodrigues LC, 33
Rogers J, 469
Rohan LC, 143
Rompalo A, 611
Rongtao Z, 26
Rose E, 205
Rosenthal SL, 655, 665, 676
Ruan Y, 623
Rubin S, 581
Rusch M, 492
Ryan C, 127, 522

S

Saidel T, 15
Saiz-Diaz RA, 350
Salakhov E, 127
Salazar LF, 205
Samoff E, 415
Sanchez C, 761
Sanders WM, 225
Sano P, 713
Schachter J, 273
Schafzin J, 581
Schechter M, 67
Schilder A, 492
Schillinger JA, 753
Schlenger W, 205
Schneeberger A, 380
Schoenbach VJ, 533
Schwebke JR, 236, 433
Secura GM, 475
Sednaoui P, 209
Seña AC, 659
Seong WK, 305
Settlage RH, 637
Shafii T, 366
Shain RN, 166, 401
Shakarishvili A, 127
Shao Y, 623
Shen C, 301
Shengji Z, 26
Shigemura K, 180
Shirakawa T, 180
Shlay JC, 154, 526
Shumin C, 26
Siedner M, 557
Silver BJ, 205
Simbayi LC, 727
Sison JD, 278
Sizemore JM Jr, 225
Skinner D, 727
Smith EM, 57
Smith L, 552
Smurzynski M, 455
Sóltz-Szöts J, 616
Sopheap S, 713
Southwick K, 127, 327
Sparks R, 113
Spielberg F, 719
St. Laurent SA, 748
St. Lawrence JS, 637
St. Louis ME, 753
Stanberry LR, 665, 676
Stary A, 616
Steece R, 259
Stein AT, 33
Sternberg MR, 753
Sterneckert K, 166
Stiffman M, 139

Stone KM, 259, 655, 665, 676
Stovel K, 366
Strand A, 331
Sudol KM, 346, 465
Suligoi B, 79, 608
Sun LP, 713
Swarnavel S, 57
Sweeney YC, 290
Swint E, 360
Swygard H, 659
Sylla LN, 682
Szwarcwald CL, 542

T

Tamaki M, 192
Tanzi E, 608
Tao G, 139
Taylor M, 552
Taylor R, 117
Taylor SN, 424
Teran S, 20
Thang BD, 15
Thomas JC, 149
Thorn M, 465
Tikhonova L, 127
Toledo-Heras M, 350
Torri A, 608
Totten PA, 113
Trees DL, 73, 702
Tschachler E, 616
Tsui HY, 568
Tu W, 655, 665, 676
Tuan NA, 15
Tucker HT, 561
Turek LP, 57
Turner KR, 517

U

Unddermans N, 727
Uthman A, 616
Uusküla A, 631

V

Valdes B, 682
Valleroy L, 475
Van Der Pol BJ, 393
Van Devanter N, 415, 637
Van Wyk R, 727
Varela JA, 761
Varkevisser CM, 265
Varner RE, 236
Vaught LC, 601
Vazquez F, 761
Viadro CI, 38
Viscidi R, 247
Voeten HACM, 265, 481
Voigt RF, 360
Vun MC, 713

W

Wald A, 508
Wallace A, 465
Wallace DR, 601
Wandera C, 522
Wang D, 57
Wang SA, 73, 702
Weeks MR, 682
Weigl S, 581
Weinstock H, 360
Weisfuse IB, 415
Weissfeld A, 273
Weiss NS, 719
Whitworth J, 650
Williams G, 163
Willis D, 273
Wilson SR, 740
Winer RL, 63
Wingood GM, 205
Wohl DA, 455
Wong EL, 561
Wright TC Jr, 174
Wroblewski JKH, 113
Wu J, 655, 665, 676
Wu Z-H, 221

X

Xia D-Y, 643
Xing H, 623
Xu F, 753

Y

Yacobson I, 561
Yankowitz J, 57
Yasuda M, 192
Yoo C, 305
Yoo J, 305
Yoshida T, 192

Z

Zaidi A, 581
Zapitz V, 557
Zeng W-J, 221
Zenilman J, 8, 52, 469
Zhongwei L, 26
Zimet GD, 428, 655, 665, 676

INDEX OF SUBJECTS

A

Accelerating sexual networks, 380, 388 (editorial)
Acetic acid gel, for bacterial vaginosis, 236
Acidification, vaginal
  for bacterial vaginosis, 236
  for chlamydial infection, 290
Acquired immunodeficiency syndrome. *See* Human immunodeficiency virus infection
Adolescents
  chlamydia and gonorrhea co-occurrence in, 424
  chlamydia screening in
    cost-effectiveness of, 85
    in nonclinical settings, 409
  condom use by, at sexual debut and subsequently, 366
  female
    bacterial vaginosis in, douching and, 433
    chlamydial infection in, in Brazil, 542
    vaginal lactobacilli in, 393
  HSV 1/2 seroprevalence/seroincidence in, in Italy, 608
  HSV-2 testing in, 665
  immunization recommendations of nurse-practitioner for, 428
  Latino, recruitment venues for, 133
  recruitment venues for, 133
  risk behaviors in, after STD diagnosis, 205
  self-reported STDs in, family socioeconomic status and, 533
  sex partner concurrence and geographic context for, 734
Africa
changing STD patterns in, after introduction of syndromic management program, 522
  health care–seeking behavior for STDs in, gender differences in, 265
  intravaginal practices in, HIV/STD prevalence and, 174
  receptivity for probiotic products among students in, 460
  relative risk in rural vs. urban areas in, 481
  scale-free sexual networks in, 380, 388 (editorial)
  STD treatment in, in private sector, 650
  theory-based HIV risk reduction counseling in, 727
  uneven HIV prevalence in, 365 (letter)
African Americans. *See also* Race/ethnicity
  risk reduction intervention for, 166
  small-group behavioral intervention for, 401
AIDS. *See* Human immunodeficiency virus infection
American Sexually Transmitted Diseases Association (ASTDA), 2003 award winners, 1, 3
Anal intercourse
  lubricants for, relative safety of, 346
  unprotected, recreational drug use and, 492
Anal squamous intraepithelial lesions, in HIV-positive men, persistence of after HAART, 96
Animal testing, for topical microbicide, 290
Anogenital herpes. *See also* Herpes simplex virus
  from HSV-1, in Scotland, 322
  polymerase chain reaction assay for, 331
Antibiotics
  for neurosyphilis, MRI/CSF-determined response to, 350
  resistance to. *See* Antimicrobial resistance
Antibody avidity test, for HSV-2, 508
  predictors of results of, 676
Antimicrobial resistance, of *N. gonorrhoeae*
  to azithromycin, 73
  in France, 209
  gyrA and *parC* mutations and, 180, 353, 616
  in Japan, 180, 353
  in Korea, 305
Antimicrobials, for neurosyphilis, MRI/CSF-determined response to, 350
Antiretroviral therapy
  differential impact on transmission dynamics, 100
  persistent anal squamous intraepithelial lesions after, 96
Apoptosis, lymphocyte, in secondary syphilis, 221
Army recruits, male, joint screening-education intervention for, 443
Asian Americans. *See also* Race/ethnicity
  men who have sex with men, HIV in, 475
Audio computer-assisted self-interviews, in history taking, 719
Australia, STD management and contact tracing in, in remote high-endemicity area, 449
Auxotyping, of *N. gonorrhoeae*, in Turkey, 628
Avidity testing, for HSV-2, 508
Azithromycin, decreased sensitivity of *N. gonorrhoeae* to, 73

B

Bacterial vaginosis
  douching and, in adolescents, 433
  in lesbian/bisexual women, 691
  in rural Chinese women, 643
  treatment compliance in, PDA documentation of, 488
  vaginal acidification for, 236
  vaginal lactobacilli in, in adolescents, 393
Barron, Almen L. (obituary), 257
Behavioral interventions, for prevention of gonorrhea and chlamydia, 401
Belgium, herpes simplex type 2 in pregnant women in, 297
Benzathine penicillin G
  for neurosyphilis, MRI/CSF-determined response to, 350
  for secondary syphilis, relapse after, 196
Bias
  in condom effectiveness studies, 588
  in STD incidence studies based on passive retrospective cohort data, 596
Bisexual women, bacterial vaginosis in, 691
Blacks. *See* African Americans; Race/ethnicity
Blood specimens, venous vs. fingerstick, for rapid syphilis testing, 557
Bowenoid papulosis, HPV-32–positive extragenital, in HIV infection, 619
Brazil
  chlamydial infection in female adolescents in, 542
  STD prevalence in women seeking HIV testing in, 67
Bridging population, clients of female sex workers as, in Peru, 337
Britain
  HSV2 seroprevalence in, 243
  scale-free sexual networks in, 380, 388 (editorial)
BufferGel, testing of in macaques, 290

C

Cambodia, STD case management in health facilities in, 713
Cameron, Caroline (ASTDA Young Investigator Award winner), 1
Candidiasis, in rural Chinese women, 643
CD4+/8+, in secondary syphilis, 221
Cerebrospinal fluid analysis, in general paresis, 350
Cervicitis. *See also specific infections*
  hormonal contraceptives and, 561
  pelvic inflammatory disease and, 301
China
  brothel-based sex workers in, HIV/AIDS awareness among, 695
  HIV transmission via injection drug use in, 623
  self-reported reproductive tract infections in women in, 643
  sex partners of Hong Kong men who have sex with men in, 568
Chlamydia trachomatis
  Gen-Probe APTIMA Combo 2 assay for, 273
  PCR assay for, first void urine vs. urogenital swab specimens for, 499
Chlamydial infection
  cervical, hormonal contraceptives and, 561
  extra-clinic testing for, 38, 409
  in female adolescents, in Brazil, 542
  with gonococcal infection, in adolescents, 424
  incomplete reporting of, in managed care organization, 139
  pelvic inflammatory disease and, class II DQ variants and, 301
  prevention of, small-group behavioral intervention vs. interactive counseling for, 401
  repeat testing for, methods of increasing, 637
  in rural Chinese women, 643
  screening for
    in detained adolescent males, cost-effectiveness of, 85
    linked with STD counseling, in male Army recruits, 443

mailed samples for, 113
in nonclinical setting, 38, 409
selective criteria for, 283
topical microbicide for, testing of in macaques, 290
vaginal acidification for, 290
Ciprofloxacin. *See also under* Quinolone
N. gonorrhoeae resistance to
in Japan, 180, 353
in Korea, 305
Circumcision, penile HPV infection and, 601
Clinic attendees. *See* Sexually transmitted diseases clinic attendees
Cognitive-behavioral intervention, for risk reduction in African Americans vs. Mexican Americans, 166
Cohorts, passive retrospective, in STD incidence studies, 596
Commercial sex workers. *See* Sex workers
Community social cohesion, STD prevalence and, 117
Compliance, with bacterial vaginosis therapy, PDA documentation of, 488
Computer-assisted self-interviews, in history taking, 719
Concordance
in perinatal transmission of HPV, 57
sexual partner, in self-reported sexual behavior, 185, 278
Concurrency
geographic context and, 734
partner's knowledge of, 437
Condom use
effectiveness studies for, sources of bias in, 588
errors in, STD prevalence and, 526
by female adolescents, position in social network and, 575
HIV superinfection and, 201
penile HPV infection and, 601
prior history of urethritis and, 225, 421
recent decrease in, 201
self-reported, sexual partner concordance in, 185, 278
at sexual debut, subsequent use and, 366
STD prevalence and, 154, 161 (editorial)
by women recently diagnosed with STD, 740
Condylomata acuminata, incidence of and insurance claims for, 748
Congenital syphilis
epidemiologic vs. clinical cases of, in Russia, 127
IgM immunoassay/Western blot test for, 123
maternal risk factors for, 33
Contact tracing, in remote area of high STD endemicity, 449
Contraception. *See also* Condom use
hormonal
chlamydial/gonococcal cervicitis and, 557
condom use and, 740
surgical, condom use and, 740
Corrections facilities. *See* Incarcerated/detained persons
Correspondence, 325, 365
Cost effectiveness, of chlamydia screening in adolescents, 85
Counseling, preventive
effectiveness of, 469
counselor demographics and, 52
for immigrants to Italy, 79
linked with STD counseling, for male Army recruits, 443
recruitment venues for, 239
for rural Chinese women, 643
for school vs. shelter children, in Eastern Europe, 670
theory-based HIV risk reduction, in South Africa, 727
vs. small-group behavioral intervention, 401
Culture-specific behavioral intervention, small group, for risk reduction, 401

D

Depot medroxyprogesterone acetate
chlamydial/gonococcal cervicitis and, 561
condom use and, 557
Detainees. *See* Incarcerated/detained persons
Diagnosis. *See also* Screening
risk behavior/disease incidence after, 205
Diagnostic testing. *See also* Screening *and specific diagnostic procedures*
outside of clinic settings, 38, 409
test types and volumes used in public health laboratories in, 259
Discharge, urethral
condom use during, 225, 421
self-referral to STD clinic for, 26
Disease control. *See* Prevention
Documentation, of compliance in bacterial vaginosis, PDAs for, 488
Douching, bacterial vaginosis and, in adolescents, 433
DQ variants, HLA class II, pelvic inflammatory disease and, 301
Drug use/abuse
injection, among street-based sex workers, 15
unprotected anal intercourse and, 492
Dry sex, HIV/STD prevalence and, in South Africa, 174
Dysuria, condom use during, 225, 421

E

Eastern Europe
adolescent health education in, 670
STD treatment in, evidence-based approaches in, 631
Editorials, 13, 63, 161, 388
Education. *See* Health education
Electronic emergency department reporting, of pelvic inflammatory disease, 327
Emotional disturbances, prevalence of in STD patients, 8, 13 (editorial)
Endometritis, pelvic inflammatory disease and, class II DQ variants in, 301
England
HSV2 seroprevalence in, 243
scale-free sexual networks in, 380, 388 (editorial)
Epidemiologic studies, recruitment venues for, 133
Epididymo-orchitis, tuberculous, in STD clinic attendees, 163
Errata, 200, 391, 516
Estonia, STD treatment in, evidence-based approaches in, 631
Ethnicity. *See* Race/ethnicity
Evidence-based treatment, in Estonia, 631

F

Females. *See* Women
Fertility, pelvic inflammatory disease and, 301
Fluoroquinolones. *See under* Quinolone
France, gonorrhea epidemiology/antibiotic resistance in, 209

G

Gay men. *See* Men who have sex with men
Gen-Probe APTIMA Combo 2 assay, for *C. trachomatis* and *N. gonorrhoeae*, 273
Gender differences. *See also* Women
in health care–seeking behavior, in Kenya, 265
in sexual biomarkers/behaviors related to HPV seroprevalence, 247
General paresis, MRI/CSF findings in, 350
Genetic mutations, in *N. gonorrhoeae*, quinolone resistance and, 180, 353, 616
Genital herpes. *See also* Herpes simplex virus
from HSV-1, in Scotland, 322
in Italian adolescents, 608
polymerase chain reaction assay for, 331
Genital warts, incidence of and health insurance claims for, 748
Geographic context, for adolescent STDs, 734
Georgia (Russia), HIV education for adolescents in, 670
Gonorrhea/gonococcal infection. *See also Neisseria gonorrhoeae*
cervical, hormonal contraceptives and, 561
with chlamydial infection, in adolescents, 424
epidemiology of
data collection for, 215
in France, 209
extra-clinic testing for, 38
pelvic inflammatory disease and, class II DQ variants and, 301
prevalence of, perceived social cohesion and, 117
prevention of, small-group behavioral intervention vs. interactive counseling for, 401
prior diagnosis of, risk-taking/health-seeking behavior and, 225
racial disparity in incidence rates for, 149
repeat, surveillance for, 373
repeat testing for, methods of increasing, 637

rescreening for, mailed samples for, 113
in rural Chinese women, 643
screening for, linked with STD counseling, in male Army recruits, 443
surveillance for
in France, 209
methodology of, 215, 373
for repeat infection, 373
symptomatic, condom use in, 225, 421
urethral discharge in
condom use and, 225, 421
self-referral to STD clinic for, 26
Great Britain
anogenital herpes from HSV-1 in, 322
HSV2 seroprevalence in, 243
scale-free sexual networks in, 380, 388 (editorial)
gyrA mutations, in *N. gonorrhoeae,* quinolone resistance and, 180, 353, 616

H

Hawaii, quinolone-resistant *N. gonorrhoeae* in, 702
Health care–seeking behavior
gender differences in, in Kenya, 265
for genital warts, 748
Health education
counselor demographics and, 52
for Eastern European adolescents, 670
effectiveness of, 469
for immigrants to Italy, 79
for male Army recruits, 52
recruitment venues for, 239
for rural Chinese women, 643
for school vs. shelter children, in Eastern Europe, 670
small-group vs. one-on-one, 401
Health insurance claims, for genital warts, 748
Hepatitis B, immunization for
predictors of acceptance of, 415
recommendation of to parents of adolescents, by nurse-practitioner, 428
Heroin. *See* Injection drug use
Herpes simplex virus type 1
anogenital herpes from, in Scotland, 322
in Italian adolescents, 608
polymerase chain reaction assay for, 331
seroprevalence trends for, 753
Herpes simplex virus type 2
antibody test for, 508
predictors of positive results in, 676
diagnosis of, psychological impact of, 517
in Italian adolescents, 608
polymerase chain reaction assay for, 331
screening for
acceptance of, 665
psychological impact of, 517
return for results after, 655
seroprevalence of
among suburban primary care patients, 311
in England, 243
in pregnant women, in Belgium, 297
Highly active antiretroviral therapy (HAART)
differential impact on transmission dynamics, 100
persistent anal squamous intraepithelial lesions after, 96
Hispanics. *See also* Race/ethnicity
immigrant, syphilis outbreak among, 20
recruitment venues for, 133
risk reduction intervention for, 166
small-group behavioral intervention for, 401
History taking, audio computer-assisted self-interviews for, 719
HIV infection. *See* Human immunodeficiency virus infection
HLA class II DQ variants, pelvic inflammatory disease and, 301
HMOs, incomplete reporting of chlamydia and, 139
Homeless adolescents, HIV education for, in Eastern Europe, 670
Homosexuals. *See* Lesbians; Men who have sex with men
Hong Kong, cross-border sex partners of men who have sex with men in, 568
Hormonal contraceptives
chlamydial/gonococcal cervicitis and, 561
condom use and, 740
Human immunodeficiency virus infection
antiretroviral therapy for
differential impact of on transmission dynamics, 100
persistent anal squamous intraepithelial lesions after, 96
in Asian American/Pacific Islander men who have sex with men, 475
attributable to trichomoniasis, 547
HPV-32–positive extragenital bowenoid papulosis in, 619
in injection drug users, in China, 623
partner notification in, 709
prevalence of
intravaginal practices and, in South Africa, 174
in syphilitic men who have sex with men, 581
preventive counseling for. *See* Counseling, preventive
superinfection, 201
syphilis in
in Ireland, 317
in men who have sex with men, 581
testing for
repeat, predictors of, 455
routine STD screening with, in Brazil, 67
uneven prevalence of, in Africa, 365 (letter)
vaginal microbicides for, measurement of efficacy of, 143
vaginal transmission of, 65
Human papillomavirus infection
autoinoculation in, 65
gender differences in sexual biomarkers/behaviors and, 247
penile, risk factors for, 601
perinatal transmission of, 57, 63 (editorial)
Human papillomavirus-32–positive extragenital bowenoid papulosis, in HIV infection, 619

I

IgM immunoassay, for congenital syphilis, 123
Immigrants
Hispanic, syphilis outbreak among, 20
in Italy, STD transmission patterns in, 79
tuberculous epididymo-orchitis in, 163
Immunization
for hepatitis B, predictors of acceptance of, 415
recommendation of to parents of adolescents, by nurse-practitioner, 428
Incarcerated/detained persons
adolescent male, cost-effectiveness of chlamydia screening for, 85
early syphilis in, 360
Incidence, based on passive retrospective cohort data, 596
Incidence rate difference, racial disparity in gonorrhea and, 149
Infertility, pelvic inflammatory disease and, 301
Injection drug use
among street-based sex workers, 15
HIV transmission via, in China, 623
Insurance claims, for genital warts, 748
Intercourse. *See* Sexual intercourse
Internet, use of to meet sex partners by men who have sex with men, 552
Interview, computer-assisted self-administered, in history taking, 719
Intravaginal practices, HIV/STD prevalence and, in South Africa, 174
Intravenous drug use. *See* Injection drug use
Ireland, syphilis outbreak in, 317
Italy
herpes simplex virus type 1/2 seroprevlance/seroincidence in, in adolescents, 608
immigrants to, STD transmission patterns in, 79

J

Japan, quinolone-resistant *N. gonorrhoeae* in, 180, 353

K

Kenya
  changing STD patterns in, after introduction of syndromic management program, 522
  health care–seeking behavior for STDs in, gender differences in, 265
  relative risk in rural vs. urban areas in, 481
Korea, ciprofloxacin-resistant *N. gonorrhoeae* in, 305
Koutsky, Laura (ASTDA Annual Achievement Award winner), 1

L

Laboratory tests, types and volumes used in public health laboratories, 259
Lactobacilli, vaginal, in adolescents, 393
Latinas/Latinos. *See also* Race/ethnicity
  immigrant, syphilis outbreak among, 20
  recruitment venues for, 133
  risk reduction intervention for, 166
  small-group behavioral intervention for, 401
Lesbians, bacterial vaginosis in, 691
Letters to editor, 325, 365
Lubricants
  anorectal, relative safety of, 346
  vaginal, slug mucosal irritation test for, 229
Lymphocyte apoptosis, in secondary syphilis, 221

M

Macaques, topical microbicide testing in, 290
Magnetic resonance imaging, in general paresis, 350
Mailed samples, for STD rescreening, 113
Managed care organization, incomplete reporting of chlamydia in, 139
Maternal risk factors, for congenital syphilis, 33
Maternal transmission, of HPV infection, 57, 63 (editorial)
Medroxyprogesterone acetate
  chlamydial/gonococcal cervicitis and, 561
  condom use and, 557
Men who have sex with men
  Asian American/Pacific Islander, HIV infection in, 475
  cross-border sex partners of, in Hong Kong, 568
  HIV-positive, persistent anal squamous intraepithelial lesions in, 96
  rectal lubricants for, relative safety of, 346
  syphilis in
    HIV prevalence in, 581
    in Ireland, 317
  unprotected anal intercourse in, recreational drug use and, 492
  use of Internet to meet sexual partners by, 552
Mental health problems, prevalence of in STD patients, 8, 13 (editorial)
Metronidazole, for bacterial vaginosis, PDA documentation of compliance with, 488
Metronidazole-resistant *Trichomonas vaginalis*, tinidazole for, 343
Mexican Americans. *See also* Latinas/Latinos; Race/ethnicity
  risk reduction intervention for, 166
Microbial resistance
  of *Neisseria gonorrhoeae*. *See Neisseria gonorrhoeae*
  of *Trichomonas vaginalis*, 343
Microbicides
  topical, testing of in macaques, 290
  vaginal
    acceptability of among high-risk urban women, 682
    applicators for, verification of proper use of, 465
    measurement of anti-HIV activity of, 143
    mucosal irritation test for, 229
Military recruits, male, joint screening-education intervention for, 443
Monkeys, topical microbicide testing in, 290
mtrR mutations, in *N. gonorrhoeae*, quinolone resistance and, 180, 353
Mucosal irritation test, for vaginal formulations, 229
Mutations, in *N. gonorrhoeae*, quinolone resistance and, 180, 353, 616
Mycoplasma genitalium, PCR assay for, first void urine vs. urogenital swab specimens for, 499

N

Neisseria gonorrhoeae
  antibiotic resistance of, 73, 180
    in France, 209
    gyrA mutations in, 180, 353, 616
    in Hawaii, 702
    in Japan, 180, 353
    in Korea, 209
    parC mutations in, 180, 353, 616
    QRDR mutations and, 180
  auxo/sero/opa-typing of, in Turkey, 628
  Gen-Probe APTIMA Combo 2 assay for, 273
  sensitivity of, to azithromycin, 73
Neonates, HPV infection in, concordance and modes of transmission in, 57, 63 (editorial)
Neurosyphilis. *See also* Syphilis
  general paresis in, MRI/CSF findings in, 350
Nigeria, receptivity for probiotic products among students in, 460
Nongonococcal urethritis
  prior diagnosis of, risk-taking/health-seeking behavior and, 225, 421
  Ureaplasma urealyticum biovars in, 192
Nonoxynol-9, slug mucosal irritation test for, 229
Nucleic acid amplification tests, for extra-clinic diagnosis of chlamydial and gonococcal infections, 38
Nurse practitioners, recommendation of STI vaccination to parents of adolescents, 428

O

Obituary, Almen L. Barron, 257
Ofloxacin. *See under* Quinolone
Opa-typing, of *N. gonorrhoeae*, in Turkey, 628
Oral contraceptives
  chlamydial/gonococcal cervicitis and, 561
  condom use and, 740
Orchitis, tuberculous, in STD clinic attendees, 163

P

parC mutations, in *N. gonorrhoeae*, quinolone resistance and, 180, 353, 616
Parran Award Lecture, 1, 3
Partner notification. *See also* Sex partners
  in HIV infection, 709
Passive retrospective cohorts, in STD incidence studies, 596
PDAs, in documenting compliance in bacterial vaginosis, 488
Pelvic inflammatory disease (PID)
  associations among HLA class II DQ variants, bacterial STDs, endometritis, and fertility in, 301
  electronic reporting of from emergency department, 327
  lifetime cost of, 325 (letter)
  in rural Chinese women, 643
Penicillin G
  for neurosyphilis, MRI/CSF-determined response to, 350
  for secondary syphilis, relapse after, 196
Perceived social cohesion, STD prevalence and, 117
Perinatal transmission, of HPV, 57, 63 (editorial)
Personal digital assistants (PDAs), in documenting compliance in bacterial vaginosis, 488
Peru, clients of female sex workers in, as bridging population, 337
Polymerase chain reaction (PCR) assay
  for *C. trachomatis*, first void urine vs. urogenital swab specimens for, 499
  for HSV types 1 and 2, 331
  for *M. genitalium*, first void urine vs. urogenital swab specimens for, 499
Pregnancy
  HPV vertical transmission in, 57, 63 (editorial)
  HSV-2 infection in, in Belgium, 297
Prevalence
  in Brazilian women seeking HIV testing, 67
  condom use and, 154, 161 (editorial)
  intravaginal practices and, in South Africa, 174
  perceived social cohesion and, 117
Prevention
  for brothel-based sex workers, in China, 695
  condom use and. *See* Condom use
  counseling for
    effectiveness of, 469

counselor demographics and, 52
for immigrants to Italy, 79
for male Army recruits, 443
recruitment venues for, 239
for rural Chinese women, 643
for school vs. shelter children, in Eastern Europe, 670
theory-based HIV risk reduction, in South Africa, 727
vs. small group behavioral intervention, 166
Primate testing, for topical microbicide, 290
Prisoners. *See* Incarcerated/detained persons
Probiotic products, students' receptivity to, in Africa, 460
Project SAFE, efficacy of, racial/ethnic factors in, 166
Prostitutes. *See* Sex workers
Psychiatric disorders, prevalence of in STD patients, 8, 13 (editorial)
Psychological impact, of HSV-2 testing, 517
Public health laboratories, test types and volumes in, 259

Q

Quinolone resistance, of *N. gonorrhoeae*
in France, 209
gyrA mutations and, 180, 353, 616
in Hawaii, 702
in Japan, 180, 353
in Korea, 305
parC mutations and, 180, 353, 616
QRDR mutations and, 180

R

Race/ethnicity
acceptability of vaginal microbicides and, 682
counselor demographics and counseling effectiveness and, 52
effectiveness of cognitive-behavior intervention for risk reduction and, 166
gonorrhea incidence rate and, 149
recruitment venues and, 133
small-group behavioral intervention vs. interactive counseling and, 401
socioeconomic status and self-reported STDs in adolescents and, 533
Rapid syphilis tests, evaluation of, 557
Recruitment venues, for hard-to-reach young persons, 133
Rectal intercourse
lubricants for, relative safety of, 346
unprotected, recreational drug use and, 492
Rectal squamous intraepithelial lesions, in HIV-positive men, persistence of after HAART, 96
Reporting, electronic, from emergency department, 327
Risk behaviors/factors. *See also* Condom use
in adolescents, changes in after STD diagnosis, 205
in African Americans vs. Mexican Americans, 166
in clients of female sex workers, in Peru, 337
concurrency and, 437, 734
in female adolescents, position in social network and, 575
geographic context and, 734
for human papillomavirus infection, gender differences in, 247
maternal, for congenital syphilis, 33
in penile HPV infection, 601
prior history of urethritis and, 225, 421
psychiatric disorders as, 8, 13 (editorial)
recent increases in, 201
recreational drug use and, in young men who have sex with men, 492
in rural Chinese women, 643
in rural vs. urban areas, in Kenya, 481
self-reported, sexual partner concordance in, 185, 278
Risk reduction. *See also* Prevention
culture/gender-specific small-group behavioral intervention for, 401
theory-based HIV risk reduction counseling for, in South Africa, 727
Russia
congenital syphilis in, 127
HIV education for adolescents in, 670

S

Scabies, in STD clinic attendees, 761
Scale-free sexual networks, 380, 388 (editorial)
Scotland, anogenital herpes from HSV-1 in, 322
Screening
for chlamydia
in detained adolescent males, cost-effectiveness of, 85
mailed samples for, 113
in male Army recruits, 443
in nonclinical setting, 38, 409
selective criteria for, 283
for gonorrhea
mailed samples for, 113
in male Army recruits, 443
for HSV-2
acceptance of, 665
psychological impact of, 517
return for results after, 655
repeat, mailed samples for, 113
for STDs, in Brazilian women seeking HIV testing, 67
for trichomoniasis, targeted use of culture in, 659
Self-interviews, audio computer-assisted, in history taking, 719
Self-referral, for urethral discharge, 26
Self-reported reproductive tract infections, in Chinese women, 643
Self-reported sexual behavior, sexual partner concordance in, 185, 278
Self-reported sexually transmitted diseases, socioeconomic status and, in adolescents, 533
Serotyping, of *N. gonorrhoeae*, in Turkey, 628
Sex partners
concordance in self-reported sexual behavior of, 185, 278
concurrency of, 437
geographic context and, 734
cross-border, of Hong Kong men who have sex with men, 568
meeting venues of, 239
Internet as, 552
notification of, in HIV infection, 709
Sex workers
brothel-based Chinese, HIV/AIDS awareness among, 695
clients of, as bridging population, in Peru, 337
street-based, IV drug use among, 15
Sexual behavior. *See also* Risk behavior/factors
self-reported, sexual partner concordance in, 185, 278
Sexual history, audio computer-assisted self-interviews for, 719
Sexual intercourse. *See also* Risk behaviors/factors
anal
lubricants for, relative safety of, 346
unprotected, recreational drug use and, 492
dry, HIV/STD prevalence and, in South Africa, 174
Sexual networks
accelerating, 380, 388 (editorial)
bridging populations in, clients of female sex workers as, in Peru, 337
differential impact of antiretroviral therapy on, 100
epidemiologic studies of, recruitment venues for, 133
scale-free, 380, 388 (editorial)
in syphilis epidemic, 611
Sexually transmitted diseases
diagnosis of. *See also* Screening
subsequent risk behavior/disease incidence after, 205
health care–seeking behavior for, gender differences in, in Kenya, 265
incidence of, based on passive retrospective cohort data, 596
management of, in remote area of high STD endemicity, 449
prevalence of
in Brazilian women seeking HIV testing, 67
condom use and, 154, 161 (editorial)
intravaginal practices and, in South Africa, 174
perceived social cohesion and, 117
prevention of. *See* Prevention
psychiatric disorders and, 8
screening for. *See* Screening
treatment of
in Cambodian health facilities, 713
in Estonia, evidence-based approaches in, 631
private-sector, in Uganda, 650
Sexually transmitted diseases clinic attendees
condom use by, disease prevalence and, 154, 161 (editorial)

penile HPV infection in, 601
predictors of acceptance of hepatitis B immunization for, 415
predictors of repeat testing and HIV seroconversion in, 455
repeat testing for, methods of increasing, 637
scabies in, 761
self-referral for urethral discharge by, 26
tuberculous epididymo-orchitis in, 163
Slug mucosal irritation test, 229
Social cohesion, STD prevalence and, 117
Social networks
epidemiologic studies of, recruitment venues for, 133
position in, risk perception, condom use, and STDs in adolescent females and, 575
Socioeconomic status, self-reported STDs and, in white vs. black adolescents, 533
South Africa
intravaginal practices in, HIV/STD prevalence and, 174
theory-based HIV risk reduction counseling in, 727
Spermicides, slug mucosal irritation test for, 229
Squamous intraepithelial anal lesions, in HIV-positive men, persistence of after HAART, 96
Substance abuse
injection drug use, by street-based sex workers, 15
unprotected anal intercourse and, 492
Support groups, female minority, for STD risk reduction, 401
Surgical contraception, condom use and, 740
Surveillance, of gonorrhea
in France, 209
methodology of, 215, 373
for repeat infections, 373
Swab, urogenital, vs. first void urine sample, for *M. genitalium/C. trachomatis*, 499
Syndromic management program, in Kenya, 522
Syphilis. *See also Treponema pallidum*
congenital
epidemiologic vs. clinical cases of, in Russia, 127
IgM immunoassay/Western blot test for, 123
maternal risk factors for, 33
early, in incarcerated/detained persons, 360
general paresis in, MRI findings in, 350
in men who have sex with men
HIV prevalence in, 581
in Ireland, 317
use of Internet to meet sexual partners and, 552
outbreaks of
in Hispanic immigrants, 20
in Ireland, 317
phase-specific network differences in, 611
rapid tests for, evaluation of, 557
secondary
benzathine penicillin G for, relapse after, 196
lymphocyte apoptosis in, 221

T

T cells, in secondary syphilis, 221
Tetracycline, *N. gonorrhoeae* resistance to, in Japan, 353
Theory-based HIV risk reduction counseling, in South Africa, 727
Thomas Parran Award Lecture, 1, 3
Tinidazole, for metronidazole-resistant *Trichomonas vaginalis*, 343
Topical microbicides, testing of in macaques, 290
Treatment
in Cambodian health facilities, 713
in Estonia, evidence-based approaches in, 631
private-sector, in Uganda, 650
Treponema pallidum. See also Syphilis
IgM immunoassay/Western blot test for, for congenital syphilis, 123
Trichomonas vaginalis, metronidazole-resistant, tinidazole for, 343
Trichomoniasis
number and cost of HIV cases attributable to, 547
in rural Chinese women, 643
screening for, targeted culture in, 659
Tubal ligation, condom use and, 740
Tuberculous epididymo-orchitis, in STD clinic attendees, 163
Turkey, *N. gonorrhoeae* auxo/sero/opa-typing in, 628

U

Uganda, STD treatment in, in private sector, 650
Ukraine, HIV education for adolescents in, 670
United Kingdom. *See* Great Britain
Ureaplasma urealyticum biovars, in nongonococcal urethritis, 192
Urethral discharge
condom use during, 225, 421
self-referral to STD clinic for, 26
Urethritis
gonococcal. *See* Gonorrhea/gonococcal infection
nongonococcal, *Ureaplasma urealyticum* biovars in, 192
prior diagnosis of, risk-taking/health-seeking behavior and, 225, 421
Urine sample, first void, vs. urogenital swab, for *M. genitalium/C. trachomatis*, 499

V

Vaccination
for hepatitis B, predictors of acceptance of, 415
recommendation of to parents of adolescents, by nurse-practitioner, 428
Vaginal acidification
for bacterial vaginosis, 236
for chlamydial infection, 290
Vaginal applicators, verification of proper use of, 465
Vaginal candidiasis, in rural Chinese women, 643
Vaginal formulations, slug mucosal irritation test for, 229
Vaginal lactobacilli, in adolescents, 393
Vaginal microbicides
acceptability of among high-risk urban women, 682
measurement of anti-HIV activity of, 143
mucosal irritation test for, 229
verification of proper use of applicator for, 465
Vaginal practices, HIV/STD prevalence and, in South Africa, 174
Vaginal transmission
of HIV, 65
of HPV, to neonate, 57, 63 (editorial)
Vaginosis. *See* Bacterial vaginosis

W

Warts, genital, incidence of and insurance claims for, 748
Western blot test, for congenital syphilis, 123
Women
diagnosed with STD, condom use by, 740
health care–seeking behavior of, in Kenya, 265
HPV seroprevalence in, sexual biomarkers/behaviors and, 247
lesbian/bisexual, bacterial vaginosis in, 691
pregnant
herpes simplex type 2 in, in Belgium, 297
HPV transmission to neonate by, 297

Y

Yeast infections, in rural Chinese women, 643

Z

Zimbabwe, scale-free sexual networks in, 380, 388 (editorial)